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I

nfection by the human protozoan parasite Leishmania can lead, depending
primarily on the parasite species, to either
cutaneous or mucocutaneous lesions, or
fatal generalized visceral infection. In
the New World, Leishmania (Viannia)
species can cause mucocutaneous leishmaniasis (MCL). Clinical MCL involves
a strong hyper-inflammatory response
and parasitic dissemination (metastasis)
from a primary lesion to distant sites,
leading to destructive metastatic secondary lesions especially in the nasopharyngal areas. Recently, we reported that
metastasizing, but not non-metastatic
strains of Leishmania (Viannia) guyanensis, have high burden of a non-segmented dsRNA virus, Leishmania RNA
Virus (LRV). Viral dsRNA is sensed by
the host Toll-like Receptor 3 (TLR3)
thereby inducing a pro-inflammatory
response and exacerbating the disease.
The presence of LRV in Leishmania
opens new perspectives not only in basic
understanding of the intimate relation
between the parasite and LRV, but also
in understanding the importance of the
inflammatory response in MCL patients.

Additionally, host factors are thought to
play significant roles in determining the
clinical course of the disease as well.
Leishmania parasites exist as freeliving promastigotes in the sand fly vector.
Following differentiation to the infective
metacyclic form, parasites are deposited in
the skin of vertebrate host by the sand fly
bite. There promastigotes encounter several host cell types including neutrophils,
dendritic cells and skin macrophages,
ultimately transiting and differentiating
into amastigotes which go on to replicate within the phagolysosome of macrophages. Leishmania parasites must change
their metabolism and adapt themselves to
this new environment, and resist the oxidative and other attacks activated by the
innate immune system of the host.
Leishmania species of the L. (Viannia)
subgenus, including mainly L. braziliensis, L. guyanensis and L. panamensis, give
rise to CL but are also responsible for
MCL in up to 5–10% of cases. MCL is
clearly distinguishable from other cutaneous leishmaniases by its chronic, latent
and metastatic behavior. It is characterized by the dissemination of parasites and
secondary distant lesions development
(metastasis), especially in the oral and
nasopharyngeal areas of the face, and is
accompanied by extensive tissue destruction concomitant with high immune cell
infiltration, intense activation of inflammatory cells and parasite presence (albeit
at low levels).1 MCL can appear concomitantly, several years after the initial
infection, or even in patients without
any CL history. MCL lesions are not selfhealing and are more resistant to antimony
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Leishmania are human protozoan parasites endemic in 88 countries, with a
disease prevalence of 12 million cases
accompanied by 80,000 annual fatalities.
These infections induce a large spectrum
of clinical pathologies, mainly cutaneous (CL), mucosal (MCL) and visceral
leishmaniasis (VL). The differences
arise primarily from infection by different Leishmania species, such as L. major,
L. braziliensis and L. infantum respectively.
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treatment than the primary lesions, with
frequent relapses. The factors responsible
for these relapses are not known; both
the emergence of antimony resistance as
well as differences among the infecting
L. (Viannia) species and its virulence have
been suggested.2,3
Reactivation of L. (Viannia) infection
can occur following stress or immunosuppression at a site of local inflammation,
raising the challenging question of how
these factors interact with slow-growing
or dormant parasites and the immune
system to favor the reemergence of disease
pathology. Thus far, little is known about
the pathogenesis of MCL, especially factors involved in the immune response of
the host, in the parasite dissemination,
or in reactivation. It is likely that both
L. (Viannia) oxidative stress and antimony
resistance as well as genetic background of
the host (e.g., particular alleles encoding
TNFα, TNFβ, IL-6, CXCR1 and CCL2/
MCP1) and particular species and/or isolate specific virulence factors are important parameters in the development of
MCL. The definition of such factors and
of the immune response of the host could
be extremely useful, not only to predict
the outcome of the disease and diagnosis
tools, but also to understand the metastatic process and the inter-relationships
of the parasite with its host. Currently the
immunological mechanisms of protection
and factors controlling relapse and avoiding reactivation of the infection are not
well understood.
In MCL, the immune response to
infection differs from that observed in
other types of leishmaniases. After a primary lesion, metastatic lesions can appear
at other body sites, accompanied by tissue inflammation. This pathology has
been associated with hyperactivity of the
specific T cell immune response, with an
exuberant, usually progressive, inflammatory response, that is not yet well understood.4 High levels of pro-inflammatory
cytokines such as IFNγ and TNFα, and
decreased responses to IL-10 and TGFβ,
have been described in references 5 and
6. MCL development is associated with
persistent immune responses having elevated pro-inflammatory mediator expression (higher levels of TNFα, CXCL10
and CCL4), with a mixed intra-lesional

Th1/Th2 phenotype and elevated cytotoxic T cell activity. However, cells from
MCL patients display impaired control of
the immune response due to a defect in
their ability to respond to IL-10.7-10 The
production of the different inflammatory
cytokines by the host is likely to increase
cellular recruitment and contribute to the
pathology of the disease. Thus by these
and potentially other mechanisms, immunological hyperactivity contributes to
MCL pathology. In turn measures diminishing uncontrolled inflammation could
be one promising alternative or complement to the conventional drug therapy.
Interestingly, treatment with the antiinflammatory TNFα inhibitor pentoxyphylline in combination with antimony
was effective in MCL patients unresponsive to antimonial therapy alone.11
The susceptibility of the golden hamster to infection with species of the
L. (Viannia) subgenus has provided a
useful experimental model of mucocutaneous leishmaniasis. Hamsters infected
with L. (Viannia) guyanensis isolated
from human MCL lesions reproduce the
metastatic phenotype with primary and
metastatic lesion development.12 Different
species and individual strains often differ
in their propensity to cause hyperinflammatory cutaneous secondary metastatic
lesions.13 Diversity was even seen within a
single strain, as infective clones from the
isolate of L. (Viannia) guyanensis (L.g.)
(WHI/BR/78/M5313) were either highly
metastatic, moderately metastatic or nonmetastatic in the hamster model. Nonmetastatic (M-) clones formed lesions only
at the site of inoculation and did not disseminate, whereas metastatic (M+) clones
gave rise to metastases in 60% to 80% of
hamsters. The metastatic phenotype was
stable over several passages and exacerbated by non-specific or immunologically
induced inflammatory responses.14,15
Molecular approaches have provided
some insights into factors potentially playing a role in MCL. One of the most surprising difference between the genomes
of L. braziliensis, L. major and L. infantum is the maintenance in L. braziliensis
of genes encoding the RNA-mediated
interference (RNAi) machinery, telomereassociated transposable elements and
splice leader-associated SLACS.16 The

RNAi machinery was recently shown
to be functional in L. braziliensis and in
L. guyanensis.17 A second remarkable feature
the presence of Leishmania RNA viruses
in many isolates of the L. (Viannia) species. These Leishmaniaviruses have been
classified as Totiviridae, which includes
RNA viruses detected in other protozoa
such as Trichomonas vaginalis and Giardia
lamblia and a variety of fungi including
Saccharomyces cerevisiae. Totiviruses have
a small unsegmented dsRNA genome
between 5–7 kb in length, which encodes
a capsid protein and a capsid-RNA dependent RNA polymerase (RDRP) fusion
protein essential for replication.
The existence of cytosolic dsRNA
viruses within Leishmania was first shown
in two L. guyanensis strains: MHOM/
SR/81/CUMC1A and MHOM/BR/75/
M4147.18,19
Currently
Leishmania
viruses are given arbitrary identifiers at
the time of discovery, namely LRV1-1
and LRV1–4 for the viruses of the
L. guyanensis CUMC-1 and L. guyanensis M4147 strain respectively. These two
viruses share an overall 76% nucleotide
sequence identity.20,21 LRV1s have since
been identified in many isolates of New
World Leishmania (L. braziliensis and
L. guyanensis), but in just one isolate of Old
World species L. major, which was showed
sufficient nucleotide sequence divergence
to be termed LRV2-1 (compare taxonomy
browser at www.ncbi.nlm.nih.gov). LRV1
are present not only in laboratory strains
of L. guyanensis and L. braziliensis but
importantly also in biopsies and parasite
cultures isolated from clinical cases of
leishmaniasis.18,19,22,23 LRV-positive strains
of Leishmania originated from both active
and healing lesions or scars of patients living in Brazil, Peru, Guyana and Colombia.
It was also shown that LRV1 can be occasionally be lost, thus far in just one line
of L. guyanensis.24 Such isogenic lines are
invaluable tools in evaluating the impact
of LRVs specifically on the parasite and on
the immune response.
The study of M+ and M- line is one
approach that may shed light on what
parameters underlie the metastatic phenotype and the hyperinflammatory response
observed in MCL patients. To investigate whether the immune response of the
host cell could serve as a readout assay we
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performed preliminary experiments on
the response of host macrophage infected
by M+ and M- lines, keeping in mind that
L. (Viannia) guyanensis could be infected
by a dsRNA virus. Using a 15k cDNA
microarray, we concluded that infection
of bone marrow derived macrophages
(BMMϕ) with M+ parasites induced 294
annotated differentially expressed genes
when compared with BMMϕ infected
with non metastatic (M-) parasites that had
at least a 1.5-fold change (p ≤ 0.05). Given
the importance of the immune response
in MCL pathology, we selected for further study genes involved in the immune
response and potentially relevant for MCL
in the human host. These included ones
showing increased expression of surface
activation markers, together with the
chemokines (CXCL10 and CCL5) and
cytokines (IL-6 and TNFα) secretion in
BMMϕ infected with metastatic (M+)
parasites. Furthermore, the increased chemokines and cytokine response to BMM
infections by M+ parasites required the
TRIF dependent TLR3 signaling pathway. Double stranded RNA is known to
bind to TLR3, and induce via TRIF an
inflammatory response with production
of CCL5, CXCL10, IL-6, TNFα and NO
by activating iNOS via NFκB.25,26 This
led us to consider the possible involvement
parasite dsRNA and specifically the LRV1
found in L. guyanensis. We confirmed that
the metastasizing promastigotes (L.g.M+
or h-MCL) contained LRV1 dsRNA, and
detected significantly high levels of LRV1
within metastasizing L.g.M+ or h-MCL
parasites (LRV1high). In contrast, nonmetastasizing L.g.M- or h-CL parasites
showed only trace levels of LRV1 RNA
(10,000-fold lower; termed LRV1low).
Treatment of BMMϕ with purified LRV1
dsRNA induced a pro-inflammatory
phenotype similar to BMMϕ infected
with LRV1high metastasizing parasites. In
addition, we detected an early upregulation of IFNβ, which is typically a sign of
an anti-viral immune response. As with
M- /LRV1low parasites, the absence of
TLR3 significantly decreased the expression of chemokines and cytokines produced in response to LRV RNA.
While naturally M+ and M- parasites
potentially harbor genetic differences
other than the presence of LRV, we were

able to show definitively that LRV1 was
responsible for the cytokine responses by
comparing isogenic L. guyanensis bearing
or lacking LRV1–4. As before, BMMϕ
infected with L.g. M4147 LRV1high produce significantly higher cytokine and
chemokine than the isogenic virusfree L.g. M4147 (LRV1neg) in a TLR3dependent manner.17,27 To analyze whether
TLR3 and LRV1 play a role in leishmaniasis development in vivo, TLR3-/-,
TLR7-/- and C57BL/6 wild-type (WT)
mice were infected in the footpad. A significant decrease in footpad swelling peak
and diminished parasite load could be
observed in mice lacking TLR3 infected
with L.g. LRV1highM+ (M5313) or L.g.
M4147 (LRV1high) parasites to compared
WT mice. No distinguishable difference
in disease phenotype was observed in
mice infected with L.g. LRV1lowM- (Lg17)
or L.g. LRV1neg (M4147) or between WT
and TLR7-/- infected mice with any parasite isolates.
Our results confirm that metastasizing
L.g. (M+) parasites derived from secondary lesions of hamsters or humans activate
host BMMϕs to secrete TNFα, IL-6,
CCL5 and CXCL10, elevated levels of
which have been associated with human
MCL. These TLR3-dependent responses
to infecting L.g. LRV1high /M+ parasites
resulted in increased disease severity in
mice. Our work provides evidence that
LRV1 within metastasizing L.g. parasites is recognized by the host to promote
inflammation, and is involved in susceptibility to infection.
One question is how the dsRNA found
normally within the viral particle is able to
interact with TLR3. We know from previous studies that 5–10% of the infecting
promastigotes are killed during the first
hours of infection.28 This killing process
takes place in the phagolysosome where
endosomal TLRs are present (Fig. 1). As
recognition of LRV1 within the metastasizing L.g. parasites arises early after
infection, we hypothesize that the viral
capsid is destroyed in the acidic milieu
prevalent in the phagolysosome, leading to
the release of LRV1 dsRNA, recognition
by TLR3, and activation of the signaling
cascade via TRIF, leading to the secretion
of IFNβ (which could act in an autocrine
loop on its receptor). In the next hours,

inflammatory cytokines and chemokines
are produced leading to the attraction of
dendritic and T cells. Importantly, both
the presence and levels of LRV are factors
impacting the host immune response, as
parasites bearing only low levels of LRV
failed to activate TLR3. Finally, other
nucleic acid derived motifs predicted to
arise for parasite destruction may contribute to the host’s response, as shown by the
somewhat diminished cytokine and chemokine production in TLR7-/- BMMϕ
infected with L.g. (M+) parasites. As these
effects were less than seen with TLR3 -/infections, and the TLR7-/- mice did not
show any reduction in disease progression or pathology, the TLR3-dependent
responses appear to dominate.
Our data show that L. guyanensis LRV
induces a specific immune response via
dsRNA binding to TLR3 and production
of IFNβ early after infection, sufficient to
modulate the initial immune response in
a way that impairs rather than promotes
killing. This is likely mediated through
the production of pro-inflammatory chemokines and cytokines, thereby increasing the host’s susceptibility to infection
and likely parasite dissemination. Thus,
Leishmania RNA virus, when present in
New World Leishmania guyanensis, plays
an important role in subverting the innate
immune response. This newly recognized
parasite factor could explain some of
the differences observed in the different
pathologies induced by Old World and
New World species. Although the murine
model is likely not fully representative
of the pathology in humans, it is instrumental for evaluating the role of LRV in
MCL. Of course, a role for LRVs in the
pathology of MCL does not exclude the
likelihood that other parasite or host factors play strong roles as well.
In the future, it will be necessary to
investigate the mechanism whereby LRVs
confer increased susceptibility to infection
with L. (Viannia) parasites, and to analyze
the critical role of cytokines and chemokines played in the host immune response.
Key questions are how LRV1, and the
associated hyper-inflammatory immune
response conspire together to yield the
metastatic phenotype, and whether antiinflammatory drugs can prevent the
development of chronic and secondary
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Figure 1. Model of the signaling cascade in response to the release of dsRNA from LRV particles, production of IFNβ and secretion of proinflammatory cytokines and chemokines. The main pathway involved in this process is highlighted in bold. (1) Phagocytosis of LRV infected promastigotes by
phagocytes (macrophages); (2) promastigotes differentiate into amatigotes, which reside in phagolysosomes; (3) death of some parasites (promastigotes and amastigotes), release of LRV and of dsRNA, which binds to TLR3; (4) activation of TLR3 via TRIF and signal transmission via the transcription factors IRF3 and NFκB; (5) activation and secretion of IFNβ; (6) binding of IFNβ to its receptor and activation of pro-inflammatory cytokines and
chemokines genes (autocrine loop); (7) synthesis and secretion of pro-inflammatory cytokines and chemokines such as TNFα, IL-6, CCL and CXCL10
leading to increased parasitemia and pathology.
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metastatic lesions. These new results
should help defining the role of LRV1 in
MCL pathology and ultimately facilitate
the introduction of new clinical strategies
to fight MCL. Since most human MCL is
caused by infections by L. braziliensis, it
will be important to determine whether
the LRV-dependent immune subversion
observed with L. guyanensis isolates is also
a key determinant of L. braziliensis MCL.
Our study on L. guyanensis has possible
applications on the prognosis, diagnosis
and treatment of MCL. As CL can emerge
prior to MCL, or can recede followed by
reactivation to MCL, the presence of LRV1
potentially allows some assessment of the
degree of MCL risk.29 Similarly, immunization against LRV1, or the identification
of anti-LRV chemotherapies, may contribute to amelioration of disease severity. The
value of such strategies depends strongly
on knowledge of the role of LRV in the
etiology of human disease, for which little
is known, and the contribution of genetic
differences in the parasite nuclear DNA
as well. One early study of human biopsy
samples did not reveal a strong association
between LRV and human disease status,
however several key parameters revealed
by our recent work were not addressed.30
Future studies are needed with a larger
and more diverse panel of MCL isolates,
identification of the infecting Leishmania
species, quantitation of LRV load, and
follows-up to assess the evolution of CL
into MCL.30 Since occasionally LRVs can
be lost in laboratory culture,27 its absence
from laboratory strains must be viewed
cautiously, and the role of LRV sequence
diversity also remains to be explored.
In conclusion, our study on MCL
immune response to a virus infecting a
parasite and modulating its virulence will
give a better understanding of the host
response to infection with New World
parasites and will provide clues as to which
unique pathways to target in the parasite
and in the macrophage so as to diminish
and potentially abolish parasite virulence
trait. Although genetic polymorphisms
in the host or in the parasite could be
involved in the outcome of the disease, our
study could have a direct impact on MCL
diagnosis (presence of a LRV1 in parasite isolates or specific immunodiagnostic
direct against LRV1 polypeptides as poor

prognosis of developing MCL) and treatment by using or developing new drugs
which block LRV1 replication, thereby
diminishing the inflammatory response
and the non-responsiveness to first line
treatment like antimony.
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